6GL3

Crystal structure of human Phosphatidylinositol 4-kinase III beta (PI4KIIIbeta) in complex with ligand 44


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.77 Å
  • R-Value Free: 0.333 
  • R-Value Work: 0.276 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Discovery of a Potent, Orally Bioavailable PI4KIII beta Inhibitor (UCB9608) Able To Significantly Prolong Allogeneic Organ Engraftment in Vivo.

Reuberson, J.Horsley, H.Franklin, R.J.Ford, D.Neuss, J.Brookings, D.Huang, Q.Vanderhoydonck, B.Gao, L.J.Jang, M.Y.Herdewijn, P.Ghawalkar, A.Fallah-Arani, F.Khan, A.R.Henshall, J.Jairaj, M.Malcolm, S.Ward, E.Shuttleworth, L.Lin, Y.Li, S.Louat, T.Waer, M.Herman, J.Payne, A.Ceska, T.Doyle, C.Pitt, W.Calmiano, M.Augustin, M.Steinbacher, S.Lammens, A.Allen, R.

(2018) J. Med. Chem. 61: 6705-6723

  • DOI: 10.1021/acs.jmedchem.8b00521

  • PubMed Abstract: 
  • The primary target of a novel series of immunosuppressive 7-piperazin-1-ylthiazolo[5,4- d]pyrimidin-5-amines was identified as the lipid kinase, PI4KIIIβ. Evaluation of the series highlighted their poor solubility and unwanted off-target activities. ...

    The primary target of a novel series of immunosuppressive 7-piperazin-1-ylthiazolo[5,4- d]pyrimidin-5-amines was identified as the lipid kinase, PI4KIIIβ. Evaluation of the series highlighted their poor solubility and unwanted off-target activities. A medicinal chemistry strategy was put in place to optimize physicochemical properties within the series, while maintaining potency and improving selectivity over other lipid kinases. Compound 22 was initially identified and profiled in vivo, before further modifications led to the discovery of 44 (UCB9608), a vastly more soluble, selective compound with improved metabolic stability and excellent pharmacokinetic profile. A co-crystal structure of 44 with PI4KIIIβ was solved, confirming the binding mode of this class of inhibitor. The much-improved in vivo profile of 44 positions it as an ideal tool compound to further establish the link between PI4KIIIβ inhibition and prolonged allogeneic organ engraftment, and suppression of immune responses in vivo.


    Organizational Affiliation

    UCB Pharma , 208 Bath Road , Slough , Berkshire SL1 3WE , United Kingdom.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Phosphatidylinositol 4-kinase beta,Phosphatidylinositol 4-kinase beta
A, B
386Homo sapiensMutation(s): 0 
Gene Names: PI4KB (PIK4CB)
EC: 2.7.1.67
Find proteins for Q9UBF8 (Homo sapiens)
Go to Gene View: PI4KB
Go to UniProtKB:  Q9UBF8
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
EMW
Query on EMW

Download SDF File 
Download CCD File 
A
(3~{S})-4-(6-azanyl-1-methyl-pyrazolo[3,4-d]pyrimidin-4-yl)-~{N}-(4-methoxy-2-methyl-phenyl)-3-methyl-piperazine-1-carboxamide
C20 H26 N8 O2
WRONAJQPZWDYAR-ZDUSSCGKSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.77 Å
  • R-Value Free: 0.333 
  • R-Value Work: 0.276 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 64.468α = 90.00
b = 69.484β = 90.00
c = 172.840γ = 90.00
Software Package:
Software NamePurpose
XSCALEdata scaling
REFMACrefinement
PHASERphasing
XDSdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2018-08-15
    Type: Initial release
  • Version 1.1: 2018-08-22
    Type: Data collection, Database references